AnyPlace MD

Mobile Monoclonal Antibody Infusion Treatment

Monoclonal antibody infusion is among the most promising treatments for mild to moderate COVID-19, the disease caused by the novel coronavirus SARS-CoV-2. Monoclonal antibodies are just like your body’s antibodies but are selected for their strong ability to resist the virus. Anyplace MD provides first and one-of-a-kind mobile antibody treatment.

APMD partners with hospitals across the United States to help fight COVID-19.

Our Solution

Why APMD Monoclonal antibody treatment

Clinical trials have shown that these treatments can decrease hospitalizations and emergency department visits. They can also reduce the amount of virus found in an infected person’s blood.

After entering your body, monoclonal antibodies look for and attach to the spike protein that sticks out of the coronavirus that causes COVID-19. When monoclonal antibodies attach to the spike protein, they can block the virus’s ability to enter cells — and slow down the infection.

FDA Authorized

In 2020, the FDA authorized several different monoclonal antibodies to treat COVID-19

Reduce Hospitalizations

Monoclonal antibodies can successfully reduce COVID-19 hospitalization rates


APMD provides first and one-of-a-kind mobile solution to serve you anywhere you need us

What to Expect

Your Ultimate COVID-19 Treatment Solution

Health care workers administer monoclonal antibodies with a one-time intravenous (IV) infusion. The IV infusion involves placing a needle in a vein and gradually sending the medicine through the IV and into the body.

The infusion takes about an hour. After the IV is removed, patients must wait at least one more hour so health care workers can watch for side effects or negative reactions.

Our Solutions

Mobile and Effective

We provide mobile monoclonal antibody infusion treatment in specialized mobile trailers or we can set up modular buildings to fit your needs

Questions & Asnwers


Monoclonal antibody treatment frequently asked questions

The most common reported side effects for bamlanivimab/etesevimab are:

  • Fever
  • Difficulty breathing
  • Rapid/slow heart rate
  • Tiredness
  • Weakness
  • Confusion

As we mentioned, APMD is the first organization that provides mobile solutions of your choice. Depending on your needs, we can either set up a modular building or have our special trailers with all the equipment to come to you.

In 2020, the Food and Drug Administration (FDA) issued an emergency use authorization (EUA) to allow monoclonal antibodies as a treatment option for COVID-19.

People who have received a monoclonal antibody infusion for COVID-19 should not be vaccinated within 90 days of their infusion. These people are eligible when the monoclonal antibodies no longer affect the vaccine.

If you already received one or both doses of the vaccine and you are eligible, you can receive this treatment.

Check with your insurance provider for more information on the cost of monoclonal antibody treatment for COVID-19.

Reach Out

Contact Us


(512) 662-2418


E. Randy Eckert, MD
Medical Director

Need Bio

Brenda Thompson,
Vice President of Human Resources

With over 20 years of Human Resource and Operations experience, Brenda brings her expertise and specialized skill set to Dental Health Management Solutions, AnyPlace MD and AnyPlace Audiology.  Her successful career includes working as an Executive Director in senior living communities and advancing her Human Resources career to Vice President of Human Resources. Brenda has a specific style and approach to balance risk-management and employee satisfaction.

Shane Stevens - AnyPlace MD- COVID-19 Testing and Treatment Solutions

Shane Stevens

Throughout my career, I have served and volunteered with several organizations including serving as an advisory board member for Concordia University Texas, an annual participant and supporter of Hounds for Heroes, the Special Olympics, and many others. I have also served as a deacon at the Austin Baptist Church since 2009. Shane earned a BS in Long-Term Health Care Administration from Texas State University in San Marcos.